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Abstract Background The utility of the PRECISE-DAPT score in predicting short-term major
bleeding, either alone, or in comparison with the CRUSADE and ACUITY scores, has not
been investigated. This analysis compared the predictive performances of the three
bleeding scores in stratifying the risk of 30-day major bleeding postpercutaneous
coronary intervention in patients with dual-antiplatelet therapy.
Methods In this post hoc subanalysis of the GLOBAL LEADERS trial, the primary safety
objective (bleeding according to the Bleeding Academic Research Consortium [BARC]
criteria [type 3 or 5]) was assessed at 30 days according to the three scores in the overall
population, and in patients with acute (ACS) and chronic coronary syndrome (CCS).
Results In a total of 15,968 patients, we calculated all three scores in 14,709 (92.1%).
Irrespectiveofclinical presentation, thePRECISE-DAPT (c-statistics: 0.648, 0.653, and0.641,
respectively), CRUSADE (c-statistics: 0.641, 0.639, and 0.644, respectively), and ACUITY (c-
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Introduction
Bleeding is a common adverse event after percutaneous
coronary intervention (PCI) and is associated with increased
morbidity and mortality.1,2 Bleeding predictors have been
described extensively; they are related mostly to the
patient’s clinical characteristics, the invasiveness of the
procedure, and the potency of the antithrombotic regimen.
In particular, the potency and duration of dual-antiplatelet
therapy (DAPT) after PCI are mainly based on the patient’s
clinical presentation (acute [ACS] or chronic coronary syn-
dromes [CCS]) and the patient’s bleeding risk.3,4 To date,
some bleeding risk scores have been validated for the pre-
diction of early and late bleeding events.
The CRUSADE (Can Rapid Risk Stratification of Unstable
Angina Patients Suppress AdverseOutcomesWith Early Imple-
mentation of the American College of Cardiology/American
Heart Association Guidelines) and ACUITY (Acute Catheteriza-
tion and Urgent Intervention Triage Strategy) bleeding risk
scores5,6 have been developed to estimate the baseline risk for
short-termmajorbleeding.7–10Historically, theCRUSADEscore
was designed for non-ST elevation myocardial infarction
(STEMI) population, whereas the ACUITY score was derived
from ACS population. Recently, the PRECISE-DAPT (Predicting
Bleeding Complication in Patients Undergoing Stent Implanta-
tion and Subsequent Dual Antiplatelet Therapy) score has been
developed from the PLATO trial (ACS population) and Bern PCI
registry (all-comers population).11Despite the development of
various bleeding scores, estimation of individual bleeding risk
remains a clinical challenge and each bleeding risk scoremight
bemore accurate in the clinical scenario fromwhich the scores
were designed. Choi et al12 have validated the PRECISE-DAPT,
CRUSADE, and ACUITY scores in an all-comers population and
showed that all three scoreshadagoodpredictiveperformance
for 1-year bleeding events. The primary endpoint in the
PRECISE-DAPT trial11 was bleeding up to 12 months after the
index PCI procedure, and therefore the utility of the PRECISE-
DAPTscore inpredictingshort-termbleedingeventspost-PCI in
patients with DAPT, either alone, or in comparison with the
CRUSADE and ACUITY scores, has not yet been investigated.
Our study sought to evaluate and compare the perform-
ances of the PRECISE-DAPT, CRUSADE, and ACUITY scores for
predicting 30-day major bleeding post-PCI in patients with
DAPT in the overall population of the GLOBAL LEADERS trial,
as well as in patients with ACS and CCS.13
Methods
Study Population
This article is a post hoc analysis of the GLOBAL LEADERS
trial, a multicenter, prospective, and open-label randomized
controlled trial (NCT01813435).14,15 Details of the study
design and protocol have been reported elsewhere.16 In brief,
the present study enrolled 15,991 patients at 130 hospitals in
18 countries between July 2013 to November 2015 in an “all-
comers” design: no restriction regarding the clinical presen-
tation of patients, the complexity of lesions, or the number of
stents used. Twenty-three patients withdrew consent and
requested data deletion from the database, leaving 15,968
patients in the present analysis. The trial randomly assigned
patients before PCI to either (1) the experimental strategy
with 1-month DAPT (aspirin and ticagrelor) followed by 23-
month ticagrelor monotherapy, or (2) the reference regimen
with 12-month DAPT (aspirin and either ticagrelor for ACS or
clopidogrel for CCS followed by 12-month aspirin mono-
therapy, respectively. Of note, patients with planned oral
anticoagulation were excluded. All types of anatomic lesions
were included and treated by default with Biolimus A9-
eluting stents (BioMatrix, Biosensors, Europe) of which the
use was unrestricted in number, length, and diameter.
The trial was approved by the institutional review board
at each center and followed the ethical principles of the
Declaration of Helsinki. All the patients gave written in-
formed consent prior to participation in the trial. Patients
who had any missing variables for the calculation of any
score were excluded from this analysis, and as the number
was small, there was no requirement for imputation.17
Variable Definition
The PRECISE-DAPT,11 CRUSADE,5 and ACUITY6 scores were
derived from the patients’ clinical characteristics recorded at
the time of enrolment into the study. The PRECISE-DAPT
score was derived from five variables (age, creatinine clear-
ance, hemoglobin, white blood cell count, and previous
spontaneous bleeding). The CRUSADE score was derived
from eight variables (female sex, diabetes mellitus, chronic
heart failure, valvular heart disease, heart rate, systolic blood
pressure, glomerular filtration rate, and hematocrit). The
ACUITY score consists of seven variables (female sex, age,
type of ACS: unstable angina, non-STEMI, or STEMI, serum
creatinine, andwhite blood cell count; all analyzed as ordinal
differences in discriminatory performance for BARC 3 or 5 bleeding up to 30 days, and
similarly the PRECISE-DAPTscorehada comparable discriminative capacity according to the
integrated discrimination improvement when compared with the other scores. In ACS, the
CRUSADE score had a poor calibration ability (Hosmer–Lemeshow goodness-of-fit [GOF]
chi-square¼ 15.561, p¼ 0.049), whereas in CCS, the PRECISE-DAPT score had poor
calibration (GOF chi-square¼ 15.758, p¼ 0.046).
Conclusion The PRECISE-DAPT score might be clinically useful in the overall popula-
tion and ACS patients for the prediction of short-term major bleeding considering its
discriminative and calibration abilities.
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categories). Hemoglobin equals to 0, 999.9, and less than 3.1
andwhite blood cell count> 30 or equals to 0 were excluded
and treated asmissing value. The total scores for each patient
were assessed using an online calculator (Sikuli app [http://
sikulix.com]) with all the prognostic variables included in
the score.
Study Objectives
The primary objective was to compare the predictive perfor-
mance of the PRECISE-DAPT, CRUSADE, and ACUITY scores
for Bleeding Academic Research Consortium (BARC) 3 or 5
bleeding at 30 days post-PCI in the overall population and in
patients with ACS and CCS. In the GLOBAL LEADERS trial,
bleeding events based on the BARC criteria were site-
reported, and were the only bleeding criteria used in this
trial. No other secondary endpoints were assessed in this
study.
Statistical Analysis
Quantitative variables are reported as mean standard devi-
ation or median and interquartile range. Qualitative variables
are expressed as numeric values and percentages. The dis-
criminative capacities of the three scoreswere assessedwith c-
statistics and they were compared using the DeLong test.18 A
p-value of< 0.05 was considered statistically significant. Re-
cent expert opinion refers to a c-statistics< 0.60 as poor
discrimination; 0.60 to0.75aspossiblyhelpfuldiscrimination;
and more than 0.75 as clearly useful discrimination.19 The
discriminative capacities of the three scores were also com-
pared by integrated discrimination improvement (IDI).20 In
addition, relative IDI, which defined as the increase in dis-
crimination slopes divided by the slope of the oldmodel, were
calculated to clarify the justification of IDI.21 The discrimina-
tionslope,whichwasdefinedas theslopeofa linear regression
ofpredictedprobabilitiesofaneventderived fromaprognostic
model on the binary event status, has recently gained popu-
larity as ameasure ofmodel performance.22 The calibration of
themodelswas evaluatedusing theHosmer–Lemeshowgood-
ness-of-fit (GOF) statistical test.23 A significant p-value less
than 0.05 indicated a poor calibration. All datawere processed
using SPSS version 26.0 (IBM Inc, Armonk, New York, United




Baseline characteristics in the present study are shown
in ►Table 1. In the GLOBAL LEADERS trial, complete data
to calculate the PRECISE-DAPT, CRUSADE, and ACUITY scores
were available in 14,928patients (93.5%), 15,054 patients
(94.3%), and 14,853 patients (93.0%), respectively. The 1,259
patients (7.9%) for whom the scores could not be calculated
due to missing values were excluded from this analysis.
Therefore, we calculated all three scores in 14,709 patients
(92.1%) and those patients were analyzed in the present
study. The mean value standard deviation of the PRECISE-
DAPT score in the overall population was 16.4 8.8,
Table 1 Patient characteristics
Age, y standard deviation 64.6 10.3
























Previous major bleeding 89/14,709 (0.6%)
Current smoker 3,864/14,709 (26.3%)
Impaired renal failure 2,026/14,709 (13.8%)
Clinical presentation
Chronic coronary syndrome 7,653/14,709 (52.0%)
Acute coronary syndrome 7,056/14,709 (48.0%)















PRECISE-DAPT score 16.4 8.8
CRUSADE score 20.5 12.2
ACUITY score 8.8 7.1
Abbreviations: ACUITY, Acute Catheterization and Urgent Intervention
Triage Strategy; CRUSADE, Can Rapid Risk Stratification of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implementation of the
American College of Cardiology/American Heart Association Guidelines;
PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing
Stent Implantation and Subsequent Dual Antiplatelet Therapy.
Note: Values are expressed as n (%) or mean standard deviation.
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CRUSADE score was 20.5 12.2, and the ACUITY score was
8.8 7.1, respectively. The distribution of these scores
according to each clinical presentation (the overall popula-
tion, ACS patients, and CCS patients) is shown in ►Fig. 1.
Discrimination Capacities of the Three Risk Scores
according to Each Clinical Presentation
►Table 2 shows the comparison of discriminative capacities
between the three risk scores by the DeLong test according to
each clinical presentation. In the overall population, ACS
patients, and CCS patients, respectively, the PRECISE-DAPT (c-
statistics: 0.648, 0.653, and 0.641, respectively), CRUSADE (c-
statistics: 0.641, 0.639, and 0.644, respectively), and ACUITY (c-
statistics: 0.633, 0.638, and 0.623, respectively) scores all had
possiblyhelpful discrimination abilities forBARC3or5bleeding,
with no statistically significant differences between the scores.
The IDI and relative IDI between the three risk scores
according to each clinical presentation are shown
in ►Table 3. In the overall population, the PRECISE-DAPT
score had a comparable discriminative capacity for BARC 3 or
5 bleeding when compared with the other scores (PRECISE-
DAPT score vs. CRUSADE score [reference]: IDI¼ 0.10%,
p¼ 0.249, PRECISE-DAPT score vs. ACUITY score [reference]:
IDI¼ 0.11%, p¼ 0.249, and CRUSADE score vs. ACUITY score
[reference]: IDI< 0.01%, p¼ 0.959, respectively).
In ACS patients, there was no significant difference in
discrimination for BARC 3 or 5 bleeding.
In CCS patients, the PRECISE-DAPT score had a better
discrimination for BARC 3 or 5 bleeding than the CRUSADE
and ACUITY scores (reference) (IDI¼ 0.39%, p¼ 0.017 and
IDI¼ 0.39%, p¼ 0.032, respectively).
Calibration Abilities of the Three Risk Scores according
to Each Clinical Presentation
►Table 4 shows the calibrationabilities of the three risk scores
by the Hosmer–Lemeshow GOF test according to each clinical
presentation. In the overall population, the three scores had
acceptable calibration abilities for BARC 3 or 5 bleeding.
In ACS patients, the CRUSADE score had a poor calibration
for BARC 3 or 5 bleeding (GOF chi-square¼ 15.561 and
p¼ 0.049) (►Fig. 2).
In CCS patients, the PRECISE-DAPT score had a poor
calibration for BARC 3 or 5 bleeding (GOF chi-
square¼ 15.758, p¼ 0.046).
Discussion
This is thefirst study to investigate thepredictive performance
of the PRECISE-DAPT score, in comparison with the CRUSADE
and ACUITY scores, for 30-day major bleeding post-PCI in
patients with DAPT using the GLOBAL LEADERS population.
The main findings of this study can be summarized as:
1. Irrespective of clinical presentation, the PRECISE-DAPT,
CRUSADE, and ACUITY scores had possibly helpful dis-
criminative abilities (c-statistics: 0.60 to 0.75) for 30-day
BARC 3 or 5 bleeding, with no statistically significant
differences between the scores.
Fig. 1 Histograms of PRECISE-DAPT, CRUSADE, and ACUITY score according to each clinical presentation. The red histograms show the PRECISE
DAPT score, the blue are the CRUSADE score, and the green are the ACUITY score. The overall population is shown in the top of the figure, ACS
patients are in the middle, and CCS patients are in the bottom. The three scores according to each clinical presentation are expressed as
mean standard deviation and median and interquartile range (IQR). ACS, acute coronary syndrome; ACUITY, Acute Catheterization and Urgent
Intervention Triage Strategy; CCS, chronic coronary syndrome; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; PRECISE-DAPT,
Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.
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2. In the overall population and ACS patients, the PRECISE-
DAPT score had a similar discriminative capacity for BARC
3 or 5 bleeding according to the IDI when compared with
the CRUSADE and ACUITY scores, and especially in CCS
patients, the PRECISE-DAPT score had a better discrimi-
nation than the other scores.
Table 2 Comparison of discriminative capacities between the three risk scores by DeLong test according to each clinical
presentation






c-statistics (95% CI) c-statistics (95% CI) c-statistics (95% CI) p-Value p-Value p-Value
Overall
BARC 3 or 5 0.648 (0.617–0.679) 0.641 (0.609–0.672) 0.633 (0.603–0.664) 0.531 0.223 0.549
BARC 5 0.701 (0.617–0.786) 0.694 (0.609–0.779) 0.696 (0.612–0.780) 0.854 0.875 0.941
BARC 3 0.639 (0.607–0.671) 0.637 (0.605–0.670) 0.629 (0.598–0.660) 0.861 0.397 0.514
ACS
BARC 3 or 5 0.653 (0.611–0.695) 0.639 (0.596–0.683) 0.638 (0.597–0.678) 0.406 0.343 0.915
BARC 5 0.683 (0.576–0.790) 0.708 (0.592–0.823) 0.701 (0.595–0.807) 0.652 0.646 0.862
BARC 3 0.646 (0.602–0.690) 0.638 (0.592–0.683) 0.632 (0.590–0.674) 0.605 0.385 0.744
CCS
BARC 3 or 5 0.641 (0.596–0.687) 0.644 (0.599–0.689) 0.623 (0.577–0.668) 0.876 0.265 0.184
BARC 5 0.726 (0.588–0.865) 0.676 (0.551–0.800) 0.671 (0.528–0.815) 0.251 0.212 0.895
BARC 3 0.631 (0.583–0.678) 0.639 (0.592–0.686) 0.619 (0.572–0.665) 0.633 0.498 0.240
Abbreviations: ACS, acute coronary syndrome; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; BARC, Bleeding Academic
Research Consortium; CCS, chronic coronary syndrome; CI, confidence interval; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; PRECISE-
DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.
Table 3 Integrated discrimination improvement and relative integrated discrimination improvement for bleeding events between
the three risk scores according to each clinical presentation
PRECISE-DAPT vs. CRUSADEa PRECISE-DAPT vs. ACUITYa CRUSADE vs. ACUITYa
IDI, % p-Value rIDI, % IDI, % p-Value rIDI, % IDI, % p-Value rIDI, %
Overall
BARC 3 or 5 0.10 0.249 15.5 0.11 0.249 17.0 < 0.01 0.959 < 0.01
BARC 5 –0.04 0.477 –36.8 –0.05 0.093 –46.0 –0.01 0.813 –9.2
BARC 3 0.10 0.177 17.7 0.09 0.246 15.9 –0.01 0.853 –1.8
ACS
BARC 3 or 5 –0.08 0.390 –9.3 < 0.01 0.967 < 0.01 0.09 0.263 10.4
BARC 5 –0.16 0.040 –125.4 –0.09 0.027 –70.6 0.07 0.124 54.9
BARC 3 –0.04 0.573 –5.1 0.02 0.770 2.6 0.06 0.313 7.7
CCS
BARC 3 or 5 0.39 0.017 87.8 0.39 0.032 87.8 < 0.01 0.998 < 0.01
BARC 5 0.08 0.200 87.5 0.02 0.611 21.9 –0.07 0.385 –76.5
BARC 3 0.35 0.019 46.6 0.34 0.056 60.8 –0.02 0.861 –5.5
Abbreviations: ACS, acute coronary syndrome; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; BARC, Bleeding Academic
Research Consortium; CCS, chronic coronary syndrome; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; IDI, integrated discrimination
improvement; PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet
Therapy; rIDI, relative IDI.
aThe model considered each bleeding risk score as a reference value for the others.
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3. The CRUSADE score had a poor calibration ability (GOF
chi-square¼ 15.561 and p¼ 0.049) for BARC 3 or 5 bleed-
ing in ACS patients, whereas the PRECISE-DAPT score had
poor calibration (GOF chi-square¼ 15.758, p¼ 0.046) in
CCS patients.
The CRUSADE and ACUITY scores were designed approxi-
mately 10 years ago, and currently no other newer bleeding
risk stratification scores for predicting short-term bleeding
in ACS patients exists. The patient population and medical
treatment, including the choice of antiplatelet therapy, have
changed considerably over the last decade. Notably, ticagre-
lor was not included in the armamentarium of antiplatelet
therapy in these original trials; however, in the contempo-
rary GLOBAL LEADERS trial, all ACS patients and patients
with CCS in the experimental strategy received DAPT with
ticagrelor for at least 1 month per protocol. Despite their
historical derivation, recent data show that both the CRU-
SADE and ACUITY scores have equivalent capacity for the
prediction of bleeding at 30 days after PCI, even in patients
with ACS receiving ticagrelor.9 However, the CRUSADE and
ACUITY scores are rarely used in the routine practice and are
Table 4 Calibration abilities of the three risk scores by Hosmer–Lemeshow good-of-fit test according to each clinical presentation
PRECISE-DAPT CRUSADE ACUITY
Chi-square p-Value Chi-square p-Value Chi-square p-Value
Overall
BARC 3 or 5 7.830 0.450 11.767 0.162 15.259 0.054
BARC 5 7.639 0.470 5.206 0.735 9.968 0.267
BARC 3 6.666 0.573 10.961 0.204 15.065 0.058
ACS
BARC 3 or 5 3.480 0.901 15.561 0.049 9.159 0.329
BARC 5 4.656 0.794 7.089 0.527 6.154 0.630
BARC 3 5.002 0.757 14.916 0.061 10.166 0.254
CCS
BARC 3 or 5 15.758 0.046 6.057 0.641 10.992 0.202
BARC 5 8.215 0.413 10.252 0.248 10.038 0.262
BARC 3 14.191 0.077 5.266 0.729 11.282 0.186
Abbreviations: ACS, acute coronary syndrome; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; BARC, Bleeding Academic
Research Consortium; CCS, chronic coronary syndrome; CRUSADE, Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; PRECISE-DAPT, Predicting
Bleeding Complication in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy.
Fig. 2 Calibration capacity of PRECISE-DAPT, CRUSADE, and ACUITY score for BARC 3 or 5 bleeding up to 30 days in ACS patients. Calibration
plots comparing the expected (red bar) and observed (blue bar) probabilities of BARC 3 or 5 bleeding. The left of the figure is the PRECISE-DAPT
score, the center is the CRUSADE score, and the right is the ACUITY score. ACS, acute coronary syndrome; ACUITY, Acute Catheterization and
Urgent Intervention Triage Strategy; BARC, bleeding according to the Bleeding Academic Research Consortium; CRUSADE, Can Rapid Risk
Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of
Cardiology/American Heart Association Guidelines; PRECISE-DAPT, Predicting Bleeding Complication in Patients Undergoing Stent Implantation
and Subsequent Dual Antiplatelet Therapy,.
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suitable for patients without taking oral anticoagulation.5,6
The changes in interventional practice such as the use of
radial access for coronary angiography and PCI, and the
shorter duration of DAPT might modify the predictive
performance of bleeding risk scores. Importantly, the PRE-
CISE-DAPT was developed in 2017 and was the most con-
temporary score and mostly driven by a prior history of
bleeding.11
In the present study, the PRECISE-DAPT score showed a
similar discriminative performance for major bleeding at
30 days compared with the CRUSADE and ACUITY scores in
the overall population and ACS patients, and the CRUSADE
score showed a poor calibration ability for 30-day major
bleeding in ACS patients. Recent expert opinion described
that discrimination and calibration are both important
characteristics to evaluate the predictive performance of a
risk model.19 Of note, the PRECISE-DAPT score includes
previous bleeding as one of the components in the calcula-
tion of the bleeding risk. Previous studies demonstrated
that the prevalence of history of bleeding increased the risk
of bleeding events.24–26 In the previous all-comers study,
the prevalence of history of bleeding was approximately
6%,26 whereas in the present study, a prevalence of only
0.6% was observed. This is a hypothesis-generated study
using a database of a randomized controlled trial and
bleeding events were site-reported. The PRECISE-DAPT
score showed an acceptable predictive performance for
short-term bleeding events in spite of a possible event
underreporting. In addition, the calculation of the PRE-
CISE-DAPT score is simpler and easier in terms of complet-
ing only five variables compared with the other two scores
that require many more. Therefore, the PRECISE-DAPT score
might be more useful for predicting short-term major
bleeding after 30-day DAPT post-PCI in ACS patients com-
pared with the CRUSADE score.
The PRECISE-DAPT score showed a poor calibration in
CCS patients although it had a better discrimination than
the other scores according to the IDI. One speculation for
the explanation of this result is that the PRECISE-DAPT
score derivation excluded events in the first 7 days after the
index PCI,11 whereas they were included in the present
study. Therefore, access-site-related bleedings were cap-
tured in the bleeding events at 30 days. Historically, the
CRUSADE and ACUITY scores also included these access-
site-related bleedings, and while the default access site for
PCI has moved from femoral to radial making this site of
bleeding less frequent, this should not detract from the fact
that a contemporary risk score for short-term bleeding
should include procedure-related bleedings.
Finally, the definition of bleeding events in the PRECISE-
DAPTtrial11 was originally thrombosis in myocardial in-
farction (TIMI) major or minor bleeding from day 7 or later
after the index invasive procedure up to 12 months. In the
ACUITY trial,6 the bleeding definition was TIMI major
bleeding within 30 days. In the CRUSADE trial,5 the indi-
vidual bleeding definition (intracranial hemorrhage, docu-
mented retroperitoneal bleed, hematocrit drop  12%
[baseline to nadir], any red blood cell transfusion when
baseline hematocrit was  28%, or any red blood cell
transfusion when baseline hematocrit was< 28% with
witnessed bleed) was reported as an in-hospital major
bleeding events. This difference in bleeding definition may
have affected the relatively low predictive performance of
these scores even when assessed in the same patient
population. Previous studies demonstrated that all the
three scores had a good predictive performance up to
1 year post-PCI in spite of their different bleeding defi-
nitions.12 However, to date, no validation study of bleeding
definitions up to 30 days post-PCI has been reported, and
further studies therefore would be needed to verify the
differences in the definitions.
Limitations
The present study has several limitations. First, this study is
a post hoc analysis of a neutral randomized controlled
study. Inherent subgroup analysis limitations, including
the risk of multiple testing, cannot be excluded. Therefore,
our findings should be considered as strictly hypothesis-
generating. Second, the bleeding risk and scores were
evaluated at the time of randomization, and thus at vari-
ance with the PRECISE-DAPT score which excludes the first
7 days. Third, BARC 3 or 5 bleeding was site-reported, as the
trial did not have a clinical adjudication committee for
serious adverse events due to limited financial resources.
However, seven onsite monitoring visits were performed in
each participating center, and 20% of the reported events
were checked according to source documents. In addition,
the rate of site-reported BARC 3 bleeding in the GLOBAL
LEADERS study and the rate of adjudicated BARC 3 bleeding
in the GLOBAL LEADERS Adjudication substudy (GLASSY)
were similar, a fact that excludes any serious issue of
reclassification in bleeding.27,28 Fourth, the trial was moni-
tored for event underreporting and event definition consis-
tency. Fifth, the difference in bleeding definitions used
might have affected the relatively low predictive perfor-
mance of bleeding risk scores even in the same patient
population. However, to date, no validation study of the
bleeding definitions up to 30 days post-PCI has been
reported. Finally, the Academic Research Consortium for
High Bleeding Risk (ARC-HBR) definition has been devel-
oped in 2019,29 and validated in a couple of studies.30,31 The
GLOBAL-LEADERS trial was designed in 2012 and recruited
its patients from July 2013 to November 2015.14 In the
GLOBAL-LEADERS trial, the clinical data of 3 out of 11 major
criteria of the ARC-HBR were not collected, and 5 were
exclusion criteria.
Conclusion
The PRECISE-DAPT score showed a similar discriminative
capacity for 30-day BARC 3 or 5 bleeding compared with the
CRUSADE and ACUITY scores irrespective of clinical presen-
tation, although in CCS patients, it had a poor calibration
ability. The PRECISE-DAPT score might be clinically useful in
the overall population and ACS patients for the prediction of
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30-day major bleeding post-PCI considering its discrimina-
tive and calibration abilities.
What is known about this topic?
• The PRECISE-DAPT score, which provides a standard-
ized tool for the prediction of mid-term bleeding
events during DAPT in an all-comers population, has
was developed in 2017.
What does this paper add?
• The PRECISE-DAPT score showed a similar discrimina-
tive capacity for 30-day BARC3 or 5 bleeding compared
with the CRUSADE and ACUITY scores irrespective of
clinical presentation, although in CCS patients, it had a
poor calibration ability.
• The PRECISE-DAPT score might be clinically useful in
the overall population and ACS patients for the predic-
tion of 30-day major bleeding post-PCI considering its
discriminative and calibration abilities.
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